🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Albiruni Ryan Abdul Razak

Albiruni Ryan Abdul Razak

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.”.

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9065

N/A

0DataRank · unranked

10 citations

Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato, Primo N. Lara +12 more

Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1077

N/A

0DataRank · unranked

7 citations

Hatem Soliman, Siqing Fu, Karen A. Gelmon, Albiruni Ryan Abdul Razak, Pamela N. Münster +11 more

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8563

N/A

0DataRank · unranked

0 citations

Marc R. Radke, Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato +11 more

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11528

N/A

0DataRank · unranked

3 citations

Anthony P. Conley, James Lin Chen, Elizabeth J. Davis, Melissa Burgess, Albiruni Ryan Abdul Razak +13 more